Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Recro Pharma Inc (REPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,520
  • Shares Outstanding, K 22,181
  • Annual Sales, $ 77,350 K
  • Annual Income, $ -79,720 K
  • 60-Month Beta -0.13
  • Price/Sales 2.57
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.35
  • Number of Estimates 4
  • High Estimate -0.04
  • Low Estimate -0.83
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +43.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.08 +11.26%
on 04/18/19
9.58 -6.16%
on 05/15/19
+0.76 (+9.23%)
since 04/17/19
3-Month
5.53 +62.56%
on 03/25/19
10.32 -12.89%
on 03/04/19
+0.32 (+3.69%)
since 02/15/19
52-Week
4.78 +88.08%
on 06/29/18
13.05 -31.11%
on 05/23/18
-2.04 (-18.50%)
since 05/17/18

Most Recent Stories

More News
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

ESALY : 58.9000 (+2.08%)
CPRX : 3.79 (+0.80%)
REPH : 8.99 (+0.45%)
BSTC : 64.33 (-2.53%)
Recro Pharma (REPH) Reports Q1 Loss, Tops Revenue Estimates

Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

REPH : 8.99 (+0.45%)
Recro Pharma: 1Q Earnings Snapshot

MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Friday reported a loss of $2 million in its first quarter.

REPH : 8.99 (+0.45%)
Recro Pharma Reports First Quarter 2019 Financial Results

Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results...

REPH : 8.99 (+0.45%)
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

JAZZ : 139.16 (-0.15%)
REPH : 8.99 (+0.45%)
ODT : 22.32 (+0.09%)
HJLI : 1.92 (unch)
Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019

Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conference call and audio webcast at 8:00...

REPH : 8.99 (+0.45%)
Recro Pharma, Inc. (REPH) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Recro Pharma, Inc. (REPH).

REPH : 8.99 (+0.45%)
Detailed Research: Economic Perspectives on GoPro, Recro Pharma, BrightView, Schmitt Industries, China XD Plastics Company, and Oxbridge Re -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GoPro, Inc. (NASDAQ:GPRO),...

SMIT : 2.16 (-3.57%)
BV : 16.76 (-1.24%)
GPRO : 7.06 (-2.49%)
CXDC : 2.40 (+0.84%)
OXBR : 1.25 (+4.27%)
REPH : 8.99 (+0.45%)
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville

Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed

REPH : 8.99 (+0.45%)
Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

New Meta-Analysis Data Suggests IV Meloxicam Produces Largest SPID, Greater Reduction in Opioid Use and Better Safety Profile Compared to Other Non-Opioid Medications for Moderate to Severe Pain

REPH : 8.99 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade REPH with:

Business Summary

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough...

See More

Key Turning Points

2nd Resistance Point 9.42
1st Resistance Point 9.21
Last Price 8.99
1st Support Level 8.79
2nd Support Level 8.58

See More

52-Week High 13.05
Fibonacci 61.8% 9.89
Last Price 8.99
Fibonacci 50% 8.91
Fibonacci 38.2% 7.94
52-Week Low 4.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar